[Study of the effect of combination therapy of human granulocyte-colony stimulating factor (G-CSF) and amikacin on experimental pyelonephritis induced by Pseudomonas aeruginosa in neutropenic mice].
We reported the prophylactic and therapeutic effect of human granulocyte-colony stimulating factor (G-CSF) on mice with ascending pyelonephritis induced by Pseudomonas aeruginosa (G-group). In the cyclophosphamide-treated neutropenic mice, the prophylactic administration of G-CSF (2 micrograms/day/mouse) yielded a lower incidence of infection than that of saline alone. However, the therapeutic administration of G-CSF (2 micrograms/day/mouse) did not produce decreases of the rate, suggesting that this type of administration had no effect on infection. Thus, we investigated the effect of the combination therapy of G-CSF and Amikacin. In neutropenic mice, the therapeutic administration of G-CSF alone and Amikacin (20 mg/kg) alone did not produce decreases of incidence of infection. But, combination administration of these yielded a lower incidence of infection. These results suggest that synergy of bactericidal effects of neutrophils accelerated by G-CSF with Amikacin, and a combination of these have a therapeutic effect on bacterial infection in neutropenic mice.
Department of Urology, Sapporo Medical College.
N
N
Tanaka
Y
Y
Kumamoto
T
T
Hirose
A
A
Yokoo
D000583:Amikacin / Q000627:therapeutic use*; D000818:Animals; D003131:Combined Modality Therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D051379:Mice; D008815:Mice, Inbred Strains; D009503:Neutropenia / Q000150:complications / Q000628:therapy*; D011552:Pseudomonas Infections / Q000628:therapy*; D011704:Pyelonephritis / Q000382:microbiology / Q000628:therapy*
D016179:Granulocyte Colony-Stimulating Factor; D000583:Amikacin